Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 795-800

  Meric Bernstam, F ^a,b,c   Brusco, L ^b   Daniels, M ^i,j   Wathoo, C ^b   Bailey, A M ^b   Strong, L ^j   Shaw, K ^b   Lu, K ^i,j   Qi, Y ^d   Zhao, H ^d   Lara Guerra, H ^b,m   Litton, J ^h   Arun, B ^h,j   Eterovic, A K ^g   Aytac, U ^b   Routbort, M ^f   Subbiah, V ^a   Janku, F ^a   Davies, M A ^g,k   Kopetz, S ^l   Mendelsohn, J ^b,e   Mills, G B ^b,g   Chen, K ^b,d   more..

^a Departments of Investigational Cancer Therapeutics Surgical Oncology   (United States)

^b Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy   (United States)

^c Departments of Surgical Oncology   (United States)

^d Departments of Computational Biology and Bioinformatics   (United States)

^e Departments of Genomic Medicine   (United States)

^f Departments of Hematopathology   (United States)

^g Departments of Systems Biology   (United States)

^h Departments of Breast Medical Oncology   (United States)

ⁱ Departments of Gynecologic Oncology and Reproductive Medicine   (United States)

^j Program of Clinical Cancer Genetics   (United States)

^k Departments of Melanoma Medical Oncology   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m Departments of RedSky Biomedical Institute of the Americas   (United States)

more..

Author keywords

BRCA1; Genetics; Hereditary cancer risk; Incidental results; Next generation sequencing; Personalized therapy

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53; TUBERIN; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; APC GENE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; GENE; GENE SEQUENCE; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; GERMLINE MUTATION; HUMAN; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MSH2 GENE; MSH6 GENE; NEXT GENERATION SEQUENCING; PALB2 GENE; PATHOGENIC GERMLINE VARIANT; PATIENT PREFERENCE; PRIORITY JOURNAL; PTEN GENE; RB1 GENE; SOMATIC MUTATION; TP53 GENE; TSC2 GENE; TUMOR SUPPRESSOR GENE; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; PATHOLOGY;

EXOME; GENETIC COUNSELING; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84964749942     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw018     Document Type: Article

References (22)

1. Green RC, Berg JS, Grody WW et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15(7): 565-574.
2. Jarvik GP, Amendola LM, Berg JS et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 2014; 94(6): 818-826.
3. Meric-Bernstam F, Brusco L, Shaw K et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 2015; 23: 2753-2762.
4. Chen K, Meric-Bernstam F, Zhao H et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem 2015; 61(3): 544-553.
5. Antoniou AC, Casadei S, Heikkinen T et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371(6): 497-506.
6. Szabo C, Masiello A, Ryan JF, Brody LC. The breast cancer information core: database design, structure, and scope. Hum Mutat 2000; 16(2): 123-131.
7. Petitjean A, Mathe E, Kato S et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28(6): 622-629.
8. Margraf RL, Crockett DK, Krautscheid PM et al. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 2009; 30 (4): 548-556.
9. National Comprehensive Cancer Network. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp (2 July 2015, date last accessed).
10. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68(4): 820-823.
11. NCBI. ClinVar, aggregates information about genomic variation and its relationship to human health, http://www.ncbi.nlm.nih.gov/clinvar/variation/182965/ (3 August 2015, date last accessed).
12. Schrader KA, Cheng DT, Joseph V et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol 2015; 1-8 [ePub].
13. Gonzalez-Angulo AM, Timms KM, Liu S et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17(5): 1082-1089.
14. Rahman N. Realizing the promise of cancer predisposition genes. Nature 2014; 505(7483): 302-308.
15. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 235-244.
16. Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2(1): 43-47.
17. Jinno H, Tanaka-Kagawa T, Hanioka N et al. Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos 2003; 31(1): 108-113.
18. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008; 25(1): 45-51.
19. Haga SB, Beskow LM. Ethical, legal, and social implications of biobanks for genetics research. Adv Genet 2008; 60: 505-544.
20. Bookman EB, Langehorne AA, Eckfeldt JH et al. Reporting genetic results in research studies: summary and recommendations of an NHLBI working group. Am J Med Genet A 2006; 140(10): 1033-1040.
21. Gray SW, Hicks-Courant K, Lathan CS et al. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 2012; 8(6): 329-335, 322 p following 335.
22. Yusuf RA, Rogith D, Hovick SR et al. Attitudes toward molecular testing for personalized cancer therapy. Cancer 2015; 121(2): 243-250.